Monash IVF earnings slide exposes risk in domestic recovery plan

FY26 Earnings Miss Reduced Guidance

Monash IVF Group Limited (ASX:MVF) finished FY26 with a sharp earnings contraction, as weak Australian IVF activity and a slower-moving cost base overwhelmed growth offshore. Revenue slipped 1% to A$269.5 million, but underlying EBITDA fell 19% to A$53.4 million and underlying NPAT dropped 41% to A$16.1 million, below the A$17 million to A$18 million guidance issued in June.

Statutory NPAT fell 68% to A$8.3 million. The result included a A$1.4 million after-tax write-off of prepaid assets, while the company also recorded A$6.9 million of post-tax adjustments in moving from reported to adjusted NPAT, including professional costs linked to clinic-specific incidents, commissioning expenses and restructuring costs.

The earnings miss was foreshadowed by the recently reduced FY26 profit guidance, which had followed a 4.7% decline in Australian stimulated IVF cycles. In the final result, the company said deferred East Coast price increases reduced EBITDA by approximately A$6.1 million, while domestic market-share losses and inflationary costs further pressured the Australian business.

Second-Half Market Share Recovery

The year was not uniformly weak. Monash IVF said Australian activity improved materially in the second half, with stimulated-cycle market share reaching 20.2% on a rolling six-month basis, up from 19.0% in the first half. Full-year market share was 19.5%, down from 21.0% in FY25, leaving the recovery unfinished rather than complete.

Clinical indicators remained stronger than the financial result. The group supported 5,753 clinical pregnancies, while its clinical pregnancy rate for women under 43 rose 1.8 percentage points to 42.1% and the rate for women under 40 increased to 44%. Monash IVF said both measures were above the ANZARD benchmark, although the figures describe clinical outcomes rather than earnings performance.

International Growth Softens Domestic Blow

International operations provided the clearest offset. Revenue from the segment rose 15% to A$21.2 million, while underlying EBITDA increased 10% to A$4.2 million, driven primarily by Malaysia and broader South-East Asian demand. Genetics and ancillary revenue also increased by A$4.6 million, helped by higher preimplantation genetic testing activity and storage fees.

That growth was not enough to prevent Australian underlying EBIT from falling 38% to A$24.8 million. By contrast, international underlying NPAT rose 40% to A$2.9 million. The disparity explains both the value of the overseas platform and its current limitation: it is growing, but remains too small to absorb a significant domestic downturn.

Capital Spending Gives Way to Productivity

Monash IVF spent A$23.8 million on capital expenditure in FY26, including A$10.9 million on the Brisbane fertility clinic and day hospital, A$7.9 million on laboratory and medical equipment, and A$5 million on technology. Management expects capital expenditure to fall by about 50% in FY27 as the major infrastructure cycle moves into its operating phase.

Net debt nonetheless rose A$11.6 million to A$101.2 million, with leverage at 1.9 times EBITDA. The company remains within its banking covenants and has extended its banking facility by three years, adding a further A$20 million of capacity. The balance sheet therefore has room to operate, but the next test is whether the new facilities generate enough utilisation and earnings to justify the investment.

Nurture 2030 and New Leadership

The FY27 to FY29 Nurture 2030 strategy shifts the emphasis from episodic IVF treatment towards a broader reproductive-health ecosystem spanning fertility care, diagnostics, genetics and related services. The group has also started a structural productivity program covering workforce efficiency, procurement, asset utilisation and patient administration. It reported a 1.7% reduction in variable IVF costs in the fourth quarter, but did not provide a quantified FY27 earnings benefit.

Leadership renewal adds another variable to the execution challenge. Dr Victoria Atkinson became managing director and CEO in January, Catherine West is due to become chair when Richard Davis retires in October, and Gerd Schenkel joined the board in September. The group also faces a move towards nationally consistent assisted reproductive services standards during 2027-28, increasing the importance of clinical governance and reporting systems.

Dividend Cut Leaves FY27 Proof Point

The board declared a fully franked final dividend of 1.3 cents per share, taking the FY26 total to 2.5 cents, down from 5.1 cents in FY25. That is consistent with the company’s policy of targeting a 60% to 70% payout of underlying NPAT, but also reflects the lower earnings base and the need to preserve financial flexibility.

FY27 now hinges on a fairly concrete set of measures: domestic stimulated-cycle volumes, market share in Victoria and New South Wales, pricing, productivity savings and utilisation of the completed infrastructure. The strategy offers a route back to growth, but the annual report leaves the central question unanswered: how quickly can operational improvements turn a second-half recovery into a full-year earnings recovery?